FDA CLIA waiver for ABMC's Rapid TOX drugs of abuse tests
This article was originally published in Clinica
The US FDA has granted a CLIA waiver to American Bio Medica Corporation (ABMC's) Rapid TOX point-of-care (POC) drug test product line. This means the tests can be used by non-laboratory-trained physicians and other healthcare professionals in CLIA-certified labs. The waiver covers all 14 drugs that Kinderhook, New York-based ABMC currently tests for, including amphetamines, barbiturates, marijuana and tricyclic antidepressants. The clearance also covers two different cut-off levels for the firm's opiate and cocaine tests. The tests analyse urine samples and produce results in around five minutes. ABMC hopes to complete negotiations with distributors for the hospital and physician markets, and expects to see an immediate impact on sales.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.